Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Alexion (ALXN) gains as it announces plans to initiate a study to evaluate Ultomiris for the COVID-19 infection.

Alexion to Evaluate Rare Disease Drug for COVID-19, Shares Up

The trial will start in May and will enroll 270 patients with severe cases of COVID-19.

Alexion Pharmaceuticals to Initiate Phase 3 Study for Ultomiris as a Potential Coronavirus Treatment

Alexion Pharmaceuticals (NASDAQ: ALXN) shares are trading higher on Monday. The company announced plans to initiate Phase 3 study of ULTOMIRIS in hospitalized patients with severe COVID-19.

Why Alexion's Stock Is Trading Higher Today  (ALXN)

Shares of Alexion Pharmaceuticals Inc. alxn gained 2.1% in trading on Monday morning after the drugmaker announced it plans to conduct a Phase 3 trial testing Ultomiris in patients with severe forms of COVID-19.

Alexion's stock is up after announcing trial for COVID-19 patients

Biogen

Johnson & Johnson

Novo Nordisk

Bio-Techne

Biotech and drug manufacturing companies with the strength to weather further coronavirus storms.

5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up

ACCO Brands

Blucora

PetIQ

Resideo Technologies Inc

Select Medical Holdings

Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.

6 Valuable Price-to-Book Stocks to Buy as Recession Lurks

Changyou.com Ltd.

Sanmina-SCI

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.

Coronavirus Ravaging Your Portfolio? 4 Low P/CF Stocks to Buy

Black Stone Minerals LP

You can increase the effectiveness of your search for value opportunities if you choose fairly priced or undervalued stocks.

These 3 Graham-Style Stocks Appear Fairly Priced

Western Digital

Whirlpool

Put your stimulus check to work by purchasing these deeply discounted companies.

3 Value Stocks to Buy With Your $1,200 Stimulus Check That Can Make You Rich

QIAGEN

ALXN vs. QGEN: Which Stock Is the Better Value Option?

ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?

Exelixis

Amicus Therapeutics

3 Covid-19 Proof Biotech Stocks

AbbVie

Bristol-Myers

Bargain prices and tremendous growth prospects make these stocks really attractive.

3 Dirt-Cheap Healthcare Stocks to Buy Right Now

Alexion Pharmaceuticals (ALXN) closed at $86.14 in the latest trading session, marking a +1.98% move from the prior day.

Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know

Cigna

HCA Healthcare

A stock can be cheap but not be a bargain. At least two of these stocks appear to be both.

Should You Buy These 3 Dirt-Cheap Stocks?

CVS Health

Jazz Pharmaceuticals

Teva Pharmaceutical

The coronavirus crash has pushed forward price-to-earnings ratios for these healthcare companies down to between 3 and 7.

5 Healthcare Stocks That Haven't Been This Cheap in at Least 10 Years

Amazon

Bank of America

Significant pullbacks in the market have always been an opportune time to put your money to work.

Coronavirus Stock Market Crash: 3 Stocks You Need to Own

Duke Energy

Alphabet

Buy, hold, and profit big-time from these three solid business models.

3 No-Brainer Coronavirus  Bear Market Buys

Monster Beverage

Here are some recommendations as the stock market decline continues.

Stocks This Week: Sell Short Alexion And Monster Beverage

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock?

Alexion (ALXN) Down 6.3% Since Last Earnings Report: Can It Rebound?

Gilead Sciences

ResMed

These are the health care stocks with the best value, fastest growth, and most momentum for March.

Top Health Care Stocks for March 2020

Alexion Pharmaceuticals: Pipeline Diversification Outweighs The Patent Uncertainty

Armstrong World Industries

ConocoPhillips

Crane Holdings Co

Helen of Troy

Hawkins

Paycom Software

QUALCOMM

Winmark

Initiating A Piotroski Portfolio With Nine Top-Quality Stocks

Alexion Pharmaceuticals: Revising My Valuation

Alexion Pharmaceuticals Is On Sale

Alexion Pharmaceuticals Inc (ALXN) CEO Ludwig Hantson on Q4 2019 Results - Earnings Call Transcript

News for Alexion Pharma Stock (ALXN)